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EXECUTIVE SUMMARY
Heath, Margaret. Atherosclerosis in HIV Positive Patients: A Clinical Practice Guideline
for Cardiovascular Risk Assessment and Treatment. Unpublished Doctor of
Nursing Practice Capstone Project, University of Northern Colorado, 2017.

As modern medicine allows for an increase in lifespan, patients with Human
Immunodeficiency Virus (HIV) face the same chronic health issues as other aging adults.
Among the top killers of older adult HIV patients is atherosclerosis. The following
review of literature will support the belief that HIV patients are at a higher risk for
atherosclerosis due to their chronic inflammatory state. This state in which the immune
response is elevated for a prolonged period of time provides an optimal environment for
the development of atherosclerotic plaques, as the research evidence will demonstrate.
The following guideline has been designed to assist providers in assessing an individual’s
risk and appropriate interventions in order to preserve the quality of life that this
population cherishes deeply.
There has been a growing interest in this topic as anti-retroviral therapy (ART)
becomes more targeted and effective. The importance of this guideline is to identify high
risk patients and equip providers with the knowledge to implement appropriate
interventions as quickly as possible. Early intervention will drastically decrease the levels
of atherosclerotic plaques in HIV positive patients. In conjunction with lifestyle
modifications, adherence to anti-retroviral therapy and initiating statin therapy if
appropriate, these high risk patients would be adequately prepared for the aging process.
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CHAPTER I
INTRODUCTION
Patients with human immunodeficiency virus (HIV) exhibit a two-fold increased
risk of atherosclerotic plaque development (Fitch et al., 2013). Because of this, the
primary goal for practitioners has been to identify patients who were deemed high risk
and implement appropriate measures to prevent negative sequelae of cardiovascular
disease related to plaque formation. As patients with HIV live longer, the early detection
and treatment of cardiovascular disease must take precedence in the care plan for this
population.
According to a cross-sectional study of 60 infected women and 30 non-HIV
infected women ages 18-60, HIV positive women have had an increased risk of
developing non-calcified plaques resulting in myocardial infarction and atherosclerosis
(Fitch et al., 2013). This study also correlated specific factors of the HIV disease process
(inflammation and immune activation) to the production of atherosclerosis. Further, this
risk could be compounded by lifestyle factors such as obesity, smoking, and frequent
infections.
Furthermore, the Journal for Vascular Health and Risk Management examined
HIV positive patients who were concurrently diagnosed with cardiovascular disease and
found that chronic inflammation secondary to HIV increased the severity and rate of
progression of endothelial dysfunction (Beltran et al., 2015).
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Background and Significance
Evidence has supported screening during a primary care wellness visit for an HIV
patient that would begin with a fasting lipid panel and obtainment of vital signs as well as
screening for hyperlipidemia (Depairon et al., 2001; Fitch & Grinspoon, 2011; Hulten,
Mitchell, Scally, Gibbs, & Villines, 2009; Maggi et al., 2009). These screening
techniques should be utilized for every patient, regardless of risk factors. Also, because
advanced age, sex, smoking status, and inflammatory markers all influence
cardiovascular risk in HIV positive patients (Depairon et al., 2001; Fitch et al., 2013;
Maggi et al., 2009), lifestyle modifications should be an integral part of every patient’s
care plan. Age greater than 65 years has been identified as a high-risk factor, and elderly
HIV patients must receive frequent and comprehensive screenings to prevent heart
disease.
The Framingham Risk Score (FRS) calculates the 10-year risk of coronary artery
events based upon the investigation of risk factors including sex, age, total cholesterol
level, high-density lipoprotein (HDL) level, systolic blood pressure, blood glucose level,
and smoking status. As a valid tool to predict atherosclerosis risk in HIV patients
(Maggie et al., 2009; Martin et al., 2005), the FRS should be assessed annually to detect
cardiovascular disease earlier in this high risk population (Cheruvu & Holloway 2014).
New practice recommendations advised risk factors compilation into a FRS to determine
the level of risk, then diagnostic screening by carotid intima-media thickness or coronary
angiography if the clinician deems appropriate.

3
Patients with HIV should be carefully monitored for compliance to the ART
regimen. These drugs have diminished HIV mortality rates and have been found to
reduce chronic inflammation and immune activation (Beltran et al., 2015).
Problem Statement
Health care providers must have access to a comprehensive guideline that
addresses all aspects and characteristics of the HIV disease process (endothelial
dysfunction, chronic inflammation and immune system activation, and metabolic
abnormalities). Coinfections have both contributed to and accelerated atherosclerosis;
thus, prevention of cardiovascular disease, treatment of chronic inflammation, and
continuation of ART would be key components to achieving better quality of life (Beltran
et al., 2015). Patients with HIV should be managed as a chronic infectious disease, as
high viral loads have been associated with endothelial dysfunction and the development
of atherosclerosis (Muhlestein, 2011). Treatment compliance has been influenced by
stigma, access to care, personal empowerment, and available support systems (Cahill &
Valadez, 2013). For this reason, health care providers must provide holistic care to the
HIV patient and encourage self-management of this chronic disease. Therefore, this
guideline has addressed these components and has also included the expert opinions of
those on the frontline of care for this population.
Theoretical Framework: The Stetler
Model
For the purposes of this project, the Stetler model was utilized to determine
availability of resources and the readiness of the providers being included in this project
(Terry, 2015). The five steps of the Stetler model allowed for the translation of research
into practice. Phase I was largely preparatory and included a literature review and
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identification of the problem in current practice. This project aimed to give providers one
guideline which included all the aspects recommended by current literature as well as the
provider preferences for additions to existing guidelines.
Phase II included a systematic review of literature which supported the
development of a guideline directing the diagnosis and treatment of atherosclerosis in
HIV patients. This guideline was also evaluated by the Delphi participants and adjusted
as needed. Delphi participants included one nurse practitioner, one physician assistant,
and one medical doctor. Including three different professions resulted in interdisciplinary collaboration which ultimately increased the applicability of the results of the
Delphi survey. Two rounds of surveys were administered, the first being in Phase II and
the second being in Phase III.
Phase III was the evaluation and decision-making stage which included the
second Delphi method questionnaire to identify areas which required revision and
addendums to the guideline. Participants in the Delphi survey were also asked to reach an
agreement on the items they wanted included in the guideline. The agreement reached in
the survey directly influenced the development of the guideline. Stakeholders in this
project included all providers who participated in the Delphi survey and those who may
utilize the final guideline in their practice. The stakeholders’ willingness to change was
also addressed in this stage and all were eager to participate.
Phase IV included translation and application of the guideline. During this stage,
the guideline was created for use at a clinic which focused on the primary care of HIV
positive patients. Should a clinic with this composite choose to adopt it, the guideline
would then be included in the clinical practice recommendations used by providers. This
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stage was completed after the conclusion of this capstone project as additional time was
necessary to receive approval.
Lastly, Phase V evaluated the clinical practice guideline and included a final
questionnaire for providers after 3 weeks of use regarding its helpfulness and
applicability. In this stage, the objectives were evaluated to determine the project’s
success.
Literature Review
The analysis of the literature included 19 scholarly articles. Seven of these articles
supported the suspicion that there were links between atherosclerotic plaque development
and chronic inflammation and specifically addressed the key risk factors of
atherosclerosis development. Of the treatment recommendations, preventative screening
commonly included the following tests: Carotid intima media thickness testing, coronary
computed tomography angiography, and blood laboratory testing of inflammatory
markers in high risk patients.
The majority of the studies evaluated demonstrated a positive correlation between
chronic inflammatory markers and atherosclerosis. This link validated the fact that HIV
patients, who have had prolonged elevation of their inflammatory markers, would be
susceptible to atherosclerosis. Working off of this premise, there was additional literature
examined to determine methods to decrease these risk factors such as the continuation of
ART therapy, the initiation of statin therapy, and lifestyle modifications. The review of
literature further supported the use of the Framingham Risk Score (FRS) in order to
assess the patient’s age and high sensitivity C-Reactive Protein (hs-CRP) count to
determine risk and individualized treatment plan.

Figure 1. Settler Model and its phases.
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Screening Recommendations
Regardless of risk level, screening during a primary care wellness visit for an HIV
patient should begin with a fasting lipid panel and obtainment of vital signs (Depairon et
al., 2001; Fitch & Grinspoon, 2011; Hulten et al., 2009; Maggi et al., 2009). Also,
advanced age, sex, smoking status, and inflammatory markers all influence
cardiovascular risk in HIV positive patients (Depairon et al., 2001; Fitch et al., 2013;
Maggi et al., 2009). Because age greater than 65 years has been identified as a high-risk
factor, elderly HIV patients must receive frequent and comprehensive screenings to
prevent heart disease. Therefore, being an older adult and/or current smoker would
automatically constitute high risk treatment recommendations.
In developed countries, HIV positive patients with a preliminary CD4 count
greater than 200 and compliant with long-term antiretroviral treatments (ART) have
demonstrated life expectancies past 70 years of age (Cahill & Valadez, 2013). Because of
this, a CD4 count less than 200 should result in that patient being categorized as high
risk, independent of other factors.
An extensive study by the American Heart Association and Center for Disease
Control demonstrated the inflammatory marker known as the high sensitivity C-Reactive
Protein (hs-CRP) as a strong indicator of cardiovascular disease risk in HIV patients,
(with a 10-20% risk of developing heart disease within the next 10 years), as well as a
predictor of coronary events in patients with established heart disease (Pearson et al.,
2003). Therefore, an hs-CRP should be obtained and, if greater than 3.0 mg/L, the
provider would proceed with the high risk recommendations.
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Treatment Recommendations
Once deemed high risk, these patients should be carefully monitored for
Antiretroviral Therapy (ART) regimen compliance. These drugs have diminished HIV
mortality rates and have been found to reduce chronic inflammation and immune
activation (Beltran et al., 2015). Due to adverse metabolic effects of dyslipidemia and
insulin resistance, ART, especially protease inhibitors (PIs), has remained under scrutiny
for their potentially detrimental effects. Nevertheless, a consensus of research studies
have revealed a weak relationship between HIV positive patients using protease
inhibitors and subsequent atherosclerosis development, supporting their continuation
(Beltran et al., 2015; Hulten et al., 2009; Martin et al., 2005). While PI use has not
modified values of Coronary Artery Calcification (CAC) or carotid plaque in HIV
positive patients (Hulten et al., 2009), smoking and hyperlipidemia have been identified
as having a causal relationship with thickened CIMT (Depairon et al., 2001). This
supported not only continuation of ART therapy in high risk patients but further
supported measures to increase medication regimen adherence. Methods in which
providers could assist patients with this are discussed at a later time.
Statin therapy has been another debated treatment option. Statins have been a
recommended practice for individuals greater than 75 years old with cardiovascular
disease, diabetes, and/or high low-density lipoprotein (LDL) levels (Miedema et al.,
2015). Yet, research has failed to indicate whether these findings were applicable to HIV
positive patients. Another study highlighted how targeting high LDL-cholesterol levels in
HIV infected patients were safe and effective in decreasing the FRS, however, failed to
influence CIMT development or inflammatory biomarkers after 1 year (Masiá et al.,
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2009). Rosuvasatin has currently been a lipid-lowering therapy undergoing clinical
laboratory analyses to determine its safety in HIV patients (De Lorenzo et al., 2009).
Niacin, fibrates, and fish oil have been suggested as safe medications to treat
dyslipidemia (Fitch & Grinspoon, 2011) and could be helpful in the management of LDL
levels in this population. Patients with HIV who were on statins would require frequent
fasting lipid levels, liver function tests, and creatine kinase levels, thus, the following
alternatives which require less monitoring have been encouraged as a first line treatment:
lifestyle modifications, switching the type of ART, and adding fibrates (Cheruvu &
Holloway, 2014). Research has illuminated concern that concurrent ART and statin
therapy could cause liver toxicity (Cahill & Valadez, 2013; Depairon et al., 2001).
Because of this potential harm, the implementation of statin therapy in high risk patients
has been recommended only under the following conditions: the aforementioned first line
suggestions were ineffective, the patient received frequent laboratory monitoring, and a
thorough medical history was obtained.
The major causes of death in elderly HIV patients have included cardiovascular
disease and liver disease, both adverse effects of long-term ART (Cahill & Valadez,
2013). For this reason, it has been advised to receive Computed tomography (CT)
coronary angiography and stress echocardiography to assess for coronary artery disease
in HIV patients using long-term ART (Cheruvu & Holloway, 2014). In summary, this
new proposal for treatment suggested continuation of ART as the primary medication in
HIV patients, yet long-term use would require further testing to confirm safety and
investigation of other possible medication regimens if adverse effects were predominant.
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Many HIV positive patients have exhibited significant risk factors for
atherosclerosis such as obesity, lack of exercise, diabetes, hyperlipidemia, smoking, poor
diet, ART, and sedentary lifestyle. Effective lifestyle adaptations that could decrease
atherosclerosis risk in HIV patients included: weight reduction, more than 30 minutes of
daily exercise, smoking cessation, and consuming a healthy diet (Cheruvu & Holloway,
2014; Depairon, 2001; Fitch & Grinspoon, 2011; Hulten et al., 2009). To lessen insulin
resistance, patients should be screened via oral glucose tolerance tests, switched from PIs
to another form of ART with less metabolic effects (Cheruvu & Holloway, 2014), and
treated with Metformin (Cheruvu & Holloway 2014; Fitch & Grinspoon, 2011). When
treating insulin resistance and dysplipidemia, liver and kidney functioning would require
careful monitoring (Fitch & Grinspoon, 2011). In summary, a new practice guideline
would enhance the treatment of HIV through nutrition and lifestyle modifications to
lessen cardiovascular disease risk in this population.
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CHAPTER II
PROJECT DESCRIPTION
Project Plan
The primary goal for practitioners has been to identify patients who were deemed
high risk and implement appropriate measures to prevent negative sequelae of
cardiovascular disease related to plaque formation. This project aimed to create a
guideline for providers which included evidence-based recommendations for screening
and subsequent treatment of atherosclerosis in HIV patients.
Project Objectives
The aforementioned evidence supported the need for aggressive preventative
screening and treatment in this population, which this guideline aimed to address. Three
objectives were identified to direct this project and the development of said guideline.
1.

Evaluate utilization of current guidelines which direct atherosclerosis

screening and treatment.
a.

Assess for deficits in current guidelines

b.

Determine differing clinical guideline preferences among providers
by using the Delphi method

2.

After reaching a consensus among the Delphi participants, create a

guideline to assist providers in the screening and treatment of atherosclerosis in HIV
patients
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a.

Establish current recommendations regarding screening and
treatment of atherosclerosis in the HIV positive population

3.

Assess for the guideline’s usefulness, effectiveness, and applicability

according to the providers who implement it
Project Design and Method
This project was a non-experimental, quality improvement project which aimed to
translate current research evidence into practice. The Delphi model was utilized to obtain
unanimity among providers regarding the aspects of this guideline. The Delphi model
uses questionnaires to obtain commonalities and ultimately consensus among a panel of
experts. Participation in this project was voluntary and the panelists will remain
anonymous.
Setting and Resources
This project was completed for a generic clinic setting and made available to
primary care providers. Upon completion of this capstone project, these providers were
invited to implement the guideline as part of the clinical reference directory at their
respective clinics.
There was no financial support required for this project as it was completed as
part of the requirements of the Doctor of Nursing Practice degree.
Protection of Human Subjects
This project did not involve a chart review or a database of patient information.
Providers who were included on the panel of experts were encouraged to utilize the
guideline during their assessment of patients during routine visits. No patient identifiers
were collected.
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Timeline


Phase I: Preparation
o Topic identified: August 2016
o Capstone committee established: January 2017
o Committee approved: March 2017



Phase II: Validation
o Literature review: December 2016
o Capstone proposal approved: June 30, 2017



Phase III: Evaluation
o Approval from the University of Northern Colorado Institutional Review
Board: September 15, 2017
o First Delphi questionnaire and informed consent sent to providers:
September 16, 2017



Phase IV: Translation of Evidence into Practice
o Synthesis of literature, evaluation of current practice guidelines:
completed September 30, 2017
o Cardiovascular Screening and Treatment Guideline developed: September
20, 2017



Phase V: Evaluation
o Second Delphi questionnaire sent: September 25, 2017
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Feasibility and Sustainability
The literature review and provider input via Delphi survey was used to direct the
development of this guideline. Once it was completed, providers were able to access the
guideline and make changes to it as needed.
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CHAPTER III
EVALUATION PLAN
Three objectives were established to evaluate the success of this project. The
capstone ultimately aimed to provide a comprehensive, user-friendly guideline to
providers who were caring for HIV patients.
Objective One
The current guidelines and tools used both nationally and locally were evaluated.
They were reviewed specifically in light of the most current research evidence (obtained
during the literature review) and then all providers were asked to complete the first
Delphi questionnaire.
Objective Two
Research evidence and the results of the first Delphi survey were evaluated for
usefulness within the context of this guideline. Providers were invited to make requests of
information to include in this guideline.
Objective Three
Objective three included the creation of the guideline as well as the assessment of
usability and overall provider perception by means of the questionnaire. Additions and
adjustments were made to the guideline. The final Delphi questionnaire was sent out to
obtain consensus and changes were made according to the comments and feedback of the
providers interviewed.
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CHAPTER IV
RESULTS AND OUTCOME STATEMENTS
This Capstone project aimed to assist providers in determining the best course of
action for HIV positive patients who require cardiovascular risk assessment and
subsequent treatment. There were currently several guidelines that provided direction, but
all have differences in the screening techniques and treatment recommendations. The first
objective of this project was to collect data and evaluate existing guidelines in order to
compare and contrast current recommendations being implemented by providers.
Objective One: Results from Literature
Review
Objective one was achieved through a comprehensive literature review wherein
guidelines were weighed and measured against existing literature. Several commonalities
found throughout the various guidelines were implemented into this project.
National guidelines were aimed to initiate screening for the high risk patients, as
well as implement treatment strategies to prevent or slow progression of negative
sequelae. The evidence and current guidelines overwhelming favored early and frequent
evaluation of HIV patients. If the patient exhibited additional risk factors such as
advanced age, smoking, frequent co-infections, or existing cardiovascular disease, this
warranted more in-depth diagnostic testing such as carotid intima-media thickness
(CIMT) testing and plaque visualization testing via computed tomography (CT)
angiography (Fitch & Grinspoon, 2011).
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The most prominent medical databases were scrutinized and five guidelines were
found to be commonly utilized in the treatment of dyslipidemia and cardiovascular
disease in the HIV population. The guidelines put forth by the following agencies were
closely examined: the U.S. Preventative Services Task Force (USPSTF), the American
College of Cardiology/American Heart Association (ACC/AHA), the Agency for
Healthcare Research and Quality (AHRQ), the National Institute of Health (NIH), and the
Infectious Disease Society of America (IDSA), respectively.
U.S. Preventative Services Task
Force (USPTF)
This agency provides direction and recommendations regarding the early
screening and subsequent treatment of cardiovascular disease and dyslipidemia. The
USPSTF reported reviewing literature regarding diagnostic accuracy and the efficacy of
various treatment options. Although this guideline did not specifically mention the HIV
population, it did summarize recommendations for individuals above 20 years of age and
placed them into a higher risk category. This risk level would also apply to patients who
had chronic elevation of inflammatory mediators.
The recommendation concluded that there was evidence to support the lipid
measurement of men and women who were candidates for therapy and the benefits of
screening and treating lipid disorders in high risk patients overwhelmingly outweighed
the potential harms. The preferred tests to screen for dyslipidemia were a total cholesterol
level and a HDL-C level. Abnormal results should be confirmed by repeated testing and
an average of the results should be used for subsequent treatment.

18
American College of Cardiology/
American Heart Association
(ACC/AHA)
The ACC/AHA also produced a prevention guideline for the assessment of
cardiovascular risk in 2013. The guideline provided an estimated 10-year risk
stratification based on the patient’s age, gender, and race. If completion of the
quantitative risk assessment resulted in unclear treatment recommendations, the patient’s
family history, coronary artery calcification (CAC) score, and high sensitivity C-Reactive
Protein (hs-CRP) levels should be obtained to inform medical decision making. The
guideline recommended the assessment of cardiovascular risk factors every 4 to 6 years
in patients 20-79 years of age who did not have cardiovascular disease (CVD).
The guideline was summarized in an algorithm that assessed for current CVD, the
patient’s age as well as the 10-year risk using the Pooled Cohort Equation. The guideline
assessed the 10-year risk based on the following factors: smoking and diabetes status,
cholesterol levels, the presence of hypertension, age, gender, and race. Although the
recommendation did not specifically address HIV status, many patients with HIV had
hyperlipidemia and thus, would be captured in the high risk stratification.
The Agency for Healthcare Research
and Quality-American Association
of Clinical Endocrinologists
(AHRQ)
This guideline was published in 2012 and updated a previous version from 2000.
In a four-step process, the AACE recommended a global risk assessment, screening based
on age, selection of screening tests, and the treatment of specific diagnostic findings,
respectively. The target population was anyone above the age of 2 and those at risk or
with current dyslipidemia or atherosclerosis. While the study noted that measurement of
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specific inflammatory markers were considered in the evaluation of CVD risk, they were
not recommended to be included in the screening process. This may be partly a result of
cost consideration and the expense of obtaining these laboratory results. However, CRP
levels were recommended in the screening process of adults with dyslipidemia.
The guideline also made an addendum for specific high-risk populations and
recommended close monitoring of these patients. For all patients, the lipid status should
be reassessed 6 weeks after initiation of pharmacotherapy and then 6 to 12 month
intervals. Additionally, if patients did not initially respond to pharmacotherapy, the
clinician should consider combination therapy such as Niacin added to an existing
Simvastatin regimen.
The National Institute of Health
(NIH)
In step one of this seven-step guideline, the clinician was instructed to obtain a
complete lipoprotein profile on the fasting patient. After the classification of LDL, total,
and HDL cholesterol, the provider identified the presence of other atherosclerotic disease
risk factors. In step three, the presence of major risk factors were established. These
included positive smoking status, hypertension, advanced age, and positive family history
for CVD. The Framingham Risk Assessment tool was employed to assess 10-year risk.
After this, the clinician could determine the patient’s risk category and initiate therapeutic
lifestyle changes, pharmacotherapy, or combination therapy if appropriate.
Infectious Diseases Society of America
(IDSA)
This guideline specifically addressed the abnormalities of lipid metabolism in the
HIV patient receiving antiretroviral therapy. Research demonstrated that a reduction of
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total cholesterol and an increase in serum triglycerides were associated with advanced
HIV disease and contributed to an elevated risk of CVD. The guideline recommended
obtaining a fasting lipid profile followed by the assessment of coronary artery disease
risk. The implementation of lifestyle modifications was recommended as a preliminary
step, but the alteration of ART or initiation of lipid-lowering medication was suggested if
the non-pharmacological methods are ineffective.
Objective Two: Results from Delphi
Questionnaire
The Delphi questionnaire was utilized to complete objective two by obtaining
consensus among current providers who, through their clinical practice experience and
research knowledge, were willing to participate in the formation of this guideline. The
goals of the Delphi survey were to address areas in which current guidelines were
insufficient or lacking and to utilize provider feedback to increase the usability of this
guideline. Participants represented three different specialties: nurse practitioner,
physician assistant, and a physician. All providers who participated in the survey were
currently practicing and had at least 4 years of experience. Additionally, the geographical
locations in which these providers practiced spanned across state lines. These factors
added to the usability and diverse applicability of the guideline as it was fitting for a
variety of different patient care settings because of the diversity of providers and
locations included in its creation.
Questions included in round one of the survey addressed the provider location of
current clinical practice, discipline, and specialty. The survey also inquired about whether
the provider felt like a specific guideline for cardiovascular risk in HIV patients was
currently being utilized at their respective practices, and, if so, what percentage of the
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time did they perceive providers were following it. All but one participant said that the
recommended guidelines were followed by providers “almost always.” They were also
asked about the frequency of which HIV patients were screened for cardiovascular
disease in their practice. Responses to this question varied greatly depending on the
location and type of practice. Providers at specialty clinics caring exclusively for HIV
patients said that, at least 70% of the time, patients underwent some method of screening
annually, however, in the family practice setting, the response indicated that they simply
did not know and could not provide a percentage.
Finally, the survey asked participants to indicate which of the following they
would like to have included on a guideline designed to screen for HIV cardiovascular
risk: Age, current CD4 count, current white blood cell count, length of time since HIV
diagnosis, family history as it pertained to cardiovascular health, presence of substance
abuse (alcohol, tobacco, recreational drugs), and presence of current symptoms (dyspnea,
chest pain, dizziness, hypertension). They were asked to add any other items that they
would like to see in the guideline.
Once the Delphi responses were returned, the data was recorded by the primary
investigator. Nearly all responses identified age, family history, substance abuse, and
current CD4 count as important to include. Additionally, they requested that HDL and
LDL levels, the presence of an Abacavir regimen, BMI, current diabetes, and viral load
should be added to the guideline (Appendix A).
Objective Three: Assessment of Guideline
Usability and Provided Perception
Objective three included finalizing the Delphi questionnaire and designing the
guideline. Round two of the Delphi survey revealed agreement among participants on the
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items to be included in the guideline and addressed further testing to be completed on
patients who wee deemed “high risk” based on the standards of said guideline. All agreed
that, at minimum, an EKG should be done and, if the patient was symptomatic or
hypertensive, further testing such as an echocardiogram, blood work, and a stress test
may be warranted. The treatment plan from this point forward would be based on
provider preference and would be case dependent; therefore, this was only briefly
addressed in the guideline. Upon in-depth review of the surveys, it was determined that
the value of the guideline was in its ability to identify high risk patients who may have
otherwise gone undetected rather than determine treatment regimens thereafter.
Therefore, the guideline created in partial completion of objective three included
the items that the Delphi survey participants agreed upon, along with the addition of
clinical parameters which determined if a patient should be classified as “high risk” or if
they fell within defined parameters and could proceed with bi-annual monitoring for
above mentioned risk factors. However, should the patient be outside of the parameters
for three or more items within the guideline, they would be deemed high risk and should
undergo further evaluation including an immediate EKG and additional follow-up care
including nutrition counseling and possible cardiology referral.
Key Facilitators
Key facilitators for this projects’ success included the continual collection of
literature. Committee members contributed greatly to the data collection process and
provided key articles that assisted in the development of the guideline. Without the eager,
thorough, and prompt responses from the panel of experts on the Delphi surveys, this
guideline would not have been well-rounded or provider-centered. Finally, obtaining
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Institutional Review Board approval was integral to the completion of this project (see
Appendix B).
Key Barriers
Barriers arose during the process of creating the guideline for a specific clinic.
Although this was preferred by the author and committee, complications began while
trying to organize the logistics of a clinical rotation. Although seemingly detrimental, the
guideline was designed in such a way to be applicable within a variety of patient settings.
The author also experienced difficulty with the time constraints relating to the
turnover of round one and two of the Delphi survey and this nearly posed a substantial
delay to the completion of the project. However, due to the prompt replies from the panel
of experts, there was no disruption of the project timeline.
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CHAPTER V
IMPLICATIONS FOR PRACTICE
Recommendation for Guideline
Implementation
As previously mentioned, this guideline would have a wide range of applicability
due to its design. While appropriate to use at a family medicine clinic, it would be most
useful at a specialty HIV/AIDS clinic where the patient was closely followed. The
guideline was intended primarily for use at annual physical appointments or anytime
when a full health assessment was being done. Ideally, this guideline would be reassessed every 6 months as many of the risk factors could change rapidly but, at least, it
should be assessed every 12 months.
Should a clinic choose to implement this guideline into practice, it would be
recommended that they first use it alongside the guideline they were currently using. Not
only would this make the provider’s transition into switching guidelines more smooth,
but it would shed light on the areas in which the guideline would still lacking, or perhaps
its strengths, and may provide the author with suggestions for further improvement.
Finally, before introduction of the guideline to providers, it would be
recommended that there be a staff in-service designed to educate and answer questions
about the guideline implementation process. Ultimately this guideline has been designed
as an assistive tool for providers; not a protocol mandating a treatment plan.
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Ongoing Activities and Evaluations Outside
the Scope of the Doctor of Nursing
Practice Project
Based upon discrepancies in evidence, further research recommendations include:
methods for safe statin therapy use in this population, the effects of hormone therapy
(specifically estrogen) on atherosclerosis development, and finally the most indicative
inflammatory marker to gauge atherosclerotic risk in HIV patients. Another suggestion
for research would be to examine in detail the different ART regimens to determine if
drugs other than protease inhibitors could improve patient outcomes with less metabolic
effects. More research would be necessary to discover the risk-benefit relationship
between ART used and statins in the elderly HIV patient, as quality of life usually
becomes a higher priority than lifespan in this population. Additionally, there would be
ongoing research to delineate between the various root causes of cardiovascular disease
in these patients. Additionally, family medicine clinics should equip their providers with
education regarding HIV and heart health. Providers should have heart health educational
pamphlets readily available to give to patients.
Ideally, HIV patients would be followed by providers specializing in HIV or
infectious disease because they require tailored care plans and close monitoring. Regular
and consistent follow-up would be critical to health promotion and disease prevention in
this population and, therefore, should be an integral part of their care plan.
It is recommended that at the conclusion of the five year trial period a
retrospective chart review be conducted in order to collect data and record patient
outcomes. Data obtained would include all patients flagged as high risk according to the
guideline standards. Data obtained would answer the question: What interventions were

26
ordered for these patients and what was the clinical outcome? The result of those
interventions would be important to include, as well as the current treatment plan as it
pertains to cardiovascular health. This data could then be used to examine which areas of
the guideline were still weak, as evidenced by the presence of risk factors that go
undetected or by patients that incur a cardiovascular event but were not identified as high
risk. A chart review and subsequent results comparison that reveals patients flagged as
high risk who had risk factors that were previously unaddressed would demonstrate the
usefulness of this guideline. Ongoing risk-factor analysis would be critical to the
successful implementation and evaluation of this project.
Five Criteria for Executing a Successful
Capstone Project
A Doctor of Nursing Practice Capstone project involves five essential criteria
explained as the “acronym EC as PIE” (Waldrop, Caruso, Fuchs, & Hypes, 2014, p. 301).
The first step is the enhancement of health or practice outcomes as well as health policy.
Next is the culmination of practice inquiry, followed by the development of partnerships
and the implementation or translation of research evidence into practice. Finally, the
process is completed by the evaluation of healthcare, practice, or policy outcomes
(Waldrop et al., 2014).
For the purposes of this project, the above criterion was met by first identifying
the need for a concise, user-friendly guideline that could assist providers in treating and
screening for atherosclerosis in HIV patients. Secondly, the author investigated
commonly used guidelines in the practice setting, as well as utilizing the Delphi method
to integrate provider preferences into the development of the guideline. Partnerships were
formed with providers in the HIV and family medicine communities in order to better
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understand the barriers and pitfalls of existing guidelines. Perhaps more importantly, the
partnerships allowed for a deeper understanding of the intricate details of care as it
pertains to the HIV population. Finally, the implementation and evaluation of this
guideline as outlined above. This process would extend beyond the time constraints of
this project but would be foundational to the improvement of the guideline.
Summary
The purpose of this guideline was to foremost increase the lifespan of HIV
patients. By equipping providers with a guideline that was comprehensive and userfriendly, high risk patients would be readily identified and more closely monitored.
Because of its simplicity and wide range of applicability, family medicine providers
would hopefully be more comfortable with the complex and possibly daunting task of
caring for HIV patients.
With additional time and feedback from those implementing this guideline, in the
future it may be used as a stepping stone for further treatment initiatives or assistive tools.
Providers should be encouraged to use this tool alongside their existing guideline(s) of
choice and carefully consider all aspects of each individual patient condition prior to
initiating treatment of any kind.
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APPENDIX A
GUIDELINE FOR CARDIOVASCULAR RISK ASSESSMENT
IN HIV POSITIVE PATIENTS
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GUIDELINE FOR CARDIOVASCULAR RISK ASSESSMENT
IN HIV POSITIVE PATIENTS

Which of the following applies to the patient? (Check all that apply)
____
____
____
____
____
____
____
____
____
____

60 years or older
Positive history of cardiac condition (MI, CHF, HTN)
Length of time since HIV diagnosis is greater than 5 years
First-degree relative with MI history before the age of 50
Substance abuse or tobacco history of any duration
HDL level less than 40mg/dl and LDL level greater than 160mg/dl
Viral load that exceeds one million copies/ml within the last six months
Not currently on Abacavir regimen
BMI greater than 25
Hemoglobin A1C greater than 7 OR diabetes diagnosis for ten years or

longer

If the patient has three or more of the above risk factors, they are considered high risk.
Proceed to the following algorithm:

Is the patient currently hypertensive or experiencing possible cardiac symptoms
(dizziness, dyspnea, shortness of breath, chest pain)?

YES, both

Immediate EKG
rhythm interpretation
and cardiac enzyme
lab work. Consider
echocardiogram, stress
test, cardiology
consult if indicated

HTN, no symptoms

Instruct patient to
monitor daily blood
pressure for further
evaluation. Initiate
antihypertensive
regimen if needed.

NO, neither

Continue to repeat this
evaluation and
monitor patient for
additional symptoms
or hypertension every
three months. Order
nutrition consult and
provide heart health
education (per clinic
standard)
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